相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment
Aoxiao He et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
Chunjian Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Genetic mechanisms of critical illness in COVID-19
Erola Pairo-Castineira et al.
NATURE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience
Elisabetta Xue et al.
LEUKEMIA RESEARCH (2021)
Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine
Stanislaw Supplitt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo
Xuechao Jia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting
Sreedhar Amere Subbarao
INFLAMMOPHARMACOLOGY (2021)
Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
Mauricio Sarmiento et al.
ACTA HAEMATOLOGICA (2021)
Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia
Paniz Tavakoli Shirazi et al.
CANCER LETTERS (2021)
Proteomics, Personalized Medicine and Cancer
Miao Su et al.
CANCERS (2021)
A New Patient with Inherited TYK2 Deficiency
Shokouh Azam Sarrafzadeh et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2020)
The potential and controversy of targeting STAT family members in cancer
Yannick Verhoeven et al.
SEMINARS IN CANCER BIOLOGY (2020)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N. Harrison et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira et al.
DRUGS (2020)
Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors
Alba Garrido-Trigo et al.
JOURNAL OF CROHNS & COLITIS (2020)
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
Manasi Agrawal et al.
JOURNAL OF CROHNS & COLITIS (2020)
Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage
Zhi Li et al.
PLOS ONE (2020)
Management of myelofibrosis after ruxolitinib failure
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2020)
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core
Maria-Elena Liosi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Brian S. Gerstenberger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Wei Luo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
Xiuhong Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma
Lingkai Meng et al.
BIOMED RESEARCH INTERNATIONAL (2020)
TYK2 Variants in B-Acute Lymphoblastic Leukaemia
Edgar Turrubiartes-Martinez et al.
GENES (2020)
PRECLINICAL CHARACTERIZATION OF TLL018, A NOVEL, HIGHLY POTENT AND SELECTIVE JAK1/TYK2 INHIBITOR FOR TREATING AUTOIMMUNE DISEASES
X. Liu et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The regulation of JAKs in cytokine signaling and its breakdown in disease
Henrik M. Hammaren et al.
CYTOKINE (2019)
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter C. Taylor
RHEUMATOLOGY (2019)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
Nicole Prutsch et al.
LEUKEMIA (2019)
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer
Guido Giordano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Wenjun Ouyang et al.
IMMUNITY (2019)
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Elia D. Tait Wojno et al.
IMMUNITY (2019)
Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling
Hongyu Liu et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2019)
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Stephen T. Wrobleski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
James R. Burke et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death
Wenjing Qin et al.
CANCER MEDICINE (2019)
Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
Franck J. Barrat et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Increased expression of claudin-12 promotes the metastatic phenotype of human bronchial epithelial cells and is associated with poor prognosis in lung squamous cell carcinoma
Lemeng Sun et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen et al.
CANCERS (2019)
The TYK2-P1104A Autoimmune Protective Variant Limits Coordinate Signals Required to Generate Specialized T Cell Subsets
Jacquelyn A. Gorman et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunotherapeutic effects of the TYK2 inhibitor SAR-20351 in syngeneic tumor models
John Reader et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Type I interferons in host defence and inflammatory diseases
Mary K. Crow et al.
LUPUS SCIENCE & MEDICINE (2019)
The evidence framework for precision cancer medicine
Jeffrey A. Moscow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mutations in the signal transducer and activator of transcription family of genes in cancer
Nahid Shahmarvand et al.
CANCER SCIENCE (2018)
High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer
Illja J. Diets et al.
CLINICAL CANCER RESEARCH (2018)
Epithelial Mesenchymal Transition in Tumor Metastasis
Vivek Mittal
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13 (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma
Lemeng Sun et al.
DIAGNOSTIC PATHOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases
Peng Zheng et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations
Ana Marquez et al.
GENOME MEDICINE (2018)
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
Graeme Greenfield et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Does ruxolitinib prolong the survival of patients with myelofibrosis?
Francisco Cervantes et al.
BLOOD (2017)
Clinical Genomic Profiling Identifies TYK2 Mutation and Overexpression in Patients With Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors
Angela C. Hirbe et al.
CANCER (2017)
Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
E. Waanders et al.
LEUKEMIA (2017)
Tyk2 as a target for immune regulation in human viral/bacterial pneumonia
Johanna Berg et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg et al.
ONCOTARGET (2017)
Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs
Ivan Zanoni et al.
FRONTIERS IN IMMUNOLOGY (2017)
The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions
Ryan Ferrao et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Type I interferon-mediated autoinflammation and autoimmunity
Stefanie Kretschmer et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Philadelphia chromosome-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity
Andreas Herrmann et al.
CANCER RESEARCH (2017)
Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia
Koshi Akahane et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Tyrosine kinase 2-Surveillant of tumours and bona fide oncogene
Nicole R. Leitner et al.
CYTOKINE (2017)
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
K. Akahane et al.
LEUKEMIA (2016)
Genetic abnormalities associated with acute lymphoblastic leukemia
Takafumi Yokota et al.
CANCER SCIENCE (2016)
Tyrosine kinase 2 is not limiting human antiviral type III interferon responses
Sebastian Fuchs et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
Calliope A. Dendrou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Molecular insights into regulation of JAK2 in myeloproliferative neoplasms
Olli Silvennoinen et al.
BLOOD (2015)
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
Ramona Crescenzo et al.
CANCER CELL (2015)
TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells
Laura Marroqui et al.
DIABETES (2015)
Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins
Edmond M. Linossi et al.
IMMUNOLOGICAL REVIEWS (2015)
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
Alexandra Y. Kreins et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Guarding the frontiers: the biology of type III interferons
Andreas Wack et al.
NATURE IMMUNOLOGY (2015)
TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits
Dorothee Diogo et al.
PLOS ONE (2015)
miR-744 enhances type I interferon signaling pathway by targeting PTP1B in primary human renal mesangial cells
Xiaoyan Zhang et al.
SCIENTIFIC REPORTS (2015)
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
Michaela Prchal-Murphy et al.
ONCOIMMUNOLOGY (2015)
Type I interferons in infectious disease
Finlay McNab et al.
NATURE REVIEWS IMMUNOLOGY (2015)
A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders
Thirunavukkarasu Velusamy et al.
BLOOD (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Structural basis of recognition of interferon-α receptor by tyrosine kinase 2
Heidi J. A. Wallweber et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD- mediated apoptosis
Peter S. Winter et al.
SCIENCE SIGNALING (2014)
STAT3 Target Genes Relevant to Human Cancers
Richard L. Carpenter et al.
CANCERS (2014)
The Molecular Basis of IL-10 Function: from Receptor Structure to the Onset of Signaling
Mark R. Walter
INTERLEUKIN-10 IN HEALTH AND DISEASE (2014)
a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL
Ian Flinn et al.
BLOOD (2014)
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
Greg Coffey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms
Neha Bhagwat et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Two Rare Disease-Associated Tyk2 Variants Are Catalytically Impaired but Signaling Competent
Zhi Li et al.
JOURNAL OF IMMUNOLOGY (2013)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets
Justin M. Drake et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Takaomi Sanda et al.
CANCER DISCOVERY (2013)
Establishing the role of tyrosine kinase 2 in cancer
Caroline Uebel et al.
ONCOIMMUNOLOGY (2013)
Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain
Annalisa Andreoli et al.
BLOOD (2013)
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis
Qing-Xiang Amy Sang et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
The biology and mechanism of action of suppressor of cytokine signaling 3
Jeffrey J. Babon et al.
GROWTH FACTORS (2012)
Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity
Jeffrey J. Babon et al.
IMMUNITY (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Into the Eye of the Cytokine Storm
Jennifer R. Tisoncik et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Hyper-IgE Syndromes: Lessons in Nature, From Bench to Bedside
Efren L. Rael et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2012)
Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo
Ross L. Levine et al.
BLOOD (2012)
Epithelial-mesenchymal transition, cancer stem cells and treatment resistance
Bhuvanesh Dave et al.
BREAST CANCER RESEARCH (2012)
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility
Nicolas Couturier et al.
BRAIN (2011)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity
Birgit Strobl et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
Tekla Hornakova et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The Role of Tyk2 in Regulation of Breast Cancer Growth
Qifang Zhang et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2011)
Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer
Shawna L. Organ et al.
JOURNAL OF PROTEOME RESEARCH (2011)
A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells
Catarina R. Carmo et al.
PLOS ONE (2011)
Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions
Haruko K. Shimoda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Annexin A1 attenuates EMT and metastatic potential in breast cancer
Sabine Maschler et al.
EMBO MOLECULAR MEDICINE (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Tyk2/STAT3 Signaling Mediates β-Amyloid-Induced Neuronal Cell Death: Implications in Alzheimer's Disease
Jun Wan et al.
JOURNAL OF NEUROSCIENCE (2010)
The regulation of IL-10 production by immune cells
Margarida Saraiva et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Marcin Kortylewski et al.
CANCER CELL (2009)
Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
Banibrata Sen et al.
CANCER RESEARCH (2009)
Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance
Olivia Simma et al.
CANCER RESEARCH (2009)
Proteomic identification of differentially-expressed proteins in squamous cervical cancer
Xueqiong Zhu et al.
GYNECOLOGIC ONCOLOGY (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Clinical Manifestations, Etiology, and Pathogenesis of the Hyper-IgE Syndromes
Alexandra F. Freeman et al.
PEDIATRIC RESEARCH (2009)
Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells
Hisamitsu Ide et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson et al.
BLOOD (2008)
The hyper-IgE syndromes
Alexandra F. Freeman et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines
Jens E. Ruhe et al.
CANCER RESEARCH (2007)
Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-β
M. R. Sandhya Rani et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2007)
The hyper IgE syndrome and mutations in TYK2
Cristina Woellner et al.
IMMUNITY (2007)
Distinguishing cancer-associated missense mutations from common polymorphisms
Joshua S. Kaminker et al.
CANCER RESEARCH (2007)
SOCS proteins, cytokine signalling and immune regulation
Akihiko Yoshimura et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity
Yoshiyuki Minegishi et al.
IMMUNITY (2006)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-β in primary pro-B cells
Ana M. Gamero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Structure and function of matrix metalloproteinases and TIMPs
H Nagase et al.
CARDIOVASCULAR RESEARCH (2006)
Phosphotyrosine proteomic study of interferon α signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography
HY Zheng et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain
RP Donnelly et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity
MH Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
The receptor interaction region of Tyk2 contains a motif required for its nuclear localization
J Ragimbeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
J Irie-Sasaki et al.
NATURE (2001)
Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function
K Shimoda et al.
IMMUNITY (2000)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
分享论文
